Tenvir-L Use In Pregnancy & Lactation

Pregnancy: Animal studies do not indicate direct or indirect harmful effects of tenofovir disoproxil on pregnancy, fetal development, parturition or postnatal development. The safety of tenofovir in human pregnancy has not been fully established. However, sufficient numbers of first trimester exposures have been monitored to detect at least a twofold increase in the risk of overall birth defects. No increase in birth defects was seen.
No increased risk of birth defects has been reported for lamivudine. The use of Lamivudine/Tenofovir Disoproxil Fumarate 300 mg/300 mg Tablets may be considered during pregnancy.
Breastfeeding: Lamivudine and tenofovir disoproxil are found in breast milk of lactating mothers. Current recommendations on HIV and breastfeeding (e.g. those from the WHO) should be consulted before advising patients on this matter. Preferred options may vary depending on the local circumstances.
Fertility: There are limited clinical data with respect to the effect of tenofovir disoproxil on fertility. Animal studies do not indicate harmful effects of tenofovir disoproxil on fertility. Animal studies showed that lamivudine had no effect on fertility.